Viewing Study NCT04609566

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:03 PM
Ignite Modification Date: 2026-01-29 @ 7:19 AM
Study NCT ID: NCT04609566
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-15
First Post: 2020-10-23
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
None Non-small Cell Lung Cancer View
None Squamous Cell Carcinoma of the Head and Neck View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Seattle Genetics View